Amphastar Pharmaceuticals, Inc. — Revenue by Fiscal Year
14 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/454a8eae-9d68-46c0-ba9e-e46cd2a5634c/serie/revenue
| Fiscal year | Revenue | Period | Evidence |
|---|---|---|---|
| FY 2025 | $719.9M | 2025-01-01 – 2025-12-31 | evidence 0001297184-26-000009 |
| FY 2024 | $732.0M | 2024-01-01 – 2024-12-31 | evidence 0001297184-25-000008 |
| FY 2023 | $644.4M | 2023-01-01 – 2023-12-31 | evidence 0001297184-24-000009 |
| FY 2022 | $499.0M | 2022-01-01 – 2022-12-31 | evidence 0001297184-23-000019 |
| FY 2021 | $437.8M | 2021-01-01 – 2021-12-31 | evidence 0001297184-22-000007 |
| FY 2020 | $349.8M | 2020-01-01 – 2020-12-31 | evidence 0001297184-21-000008 |
| FY 2019 | $322.4M | 2019-01-01 – 2019-12-31 | evidence 0001297184-20-000007 |
| FY 2018 | $294.7M | 2018-01-01 – 2018-12-31 | evidence 0001297184-19-000013 |
| FY 2017 | $240.2M | 2017-01-01 – 2017-12-31 | evidence 0001297184-19-000013 |
| FY 2016 | $255.2M | 2016-01-01 – 2016-12-31 | evidence 0001297184-19-000013 |
| FY 2015 | $20.8M | 2015-01-01 – 2015-12-31 | evidence 0001558370-16-005745 |
| FY 2014 | $210.5M | 2014-01-01 – 2014-12-31 | evidence 0001171843-15-001654 |
| FY 2013 | $229.7M | 2013-01-01 – 2013-12-31 | evidence 0001171843-15-001654 |
| FY 2012 | $204.3M | 2012-01-01 – 2012-12-31 | evidence 0001171843-15-001654 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
Amphastar Pharmaceuticals, Inc. — all facts · Net Income · Operating Income